Generation of a conditionally neo'-containing retroviral producer cell line: Effects of neo' on retroviral titer and transgene expression

Gene Therapy

Volumn 5, Issue 5, 1998, Pages 684-691

  Wildner, O ^a   Candotti, F ^a   Krecko, E G ^a   Xanthopoulos, K G ^a   Ramsey, W J ^a   Blaese, R M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Cre locP; GFP; Neo'; Singel gene retroviral vectors

Indexed keywords

GREEN FLUORESCENT PROTEIN; NEOMYCIN;

ADENOVIRUS; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CASSETTE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0031803564     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300654     Document Type: Article

References (53)

1. Marcel T, Grausz JD. The TMC Worldwide Gene Therapy Enrollment Report (June 1996). Hum Gene Ther 1996; 7: 2025-2046.
2. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
3. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
4. Xu L, Yee JK, Wolff JA, Friedmann T. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 1989; 171: 331-341.
5. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
6. Soriano P, Friedrich G, Lawinger P. Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J Virol 1991; 65: 2314-2319.
7. Apperley JF, Luskey BD, Williams DA. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. Blood 1991; 78: 310-317.
8. Correll PH, Colilla S, Karlsson S. Retroviral vector design for long-term expression in murine hematopoietic cells in vivo. Blood 1994; 84: 1812-1822.
9. Byun J et al. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy. Gene Therapy 1996; 3: 780-788.
10. Krall W et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Therapy 1996; 3: 37-48.
11. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982; 1: 327-341.
12. Artelt P et al. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991; 99: 249-254.
13. von Melchner H, Housman DE. The expression of neomycin phosphotransferase in human promyelocytic leukemia cells (HL60) delays their differentiation. Oncogene 1988; 2: 137-140.
14. Valera A, Perales JC Hatzoglou M, Bosch F. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum Gene Ther 1994; 5: 449-456.
15. Riddell S et al. T cell-mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996; 2: 216-223.
16. Bonini C et al. HSVtk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
17. Sternberg N, Hamilton D. Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites. J Mol Biol 1981; 150: 467-486.
18. Sternberg N, Hamilton D, Hoess R. Bacteriophage P1 site-specific recombination. II. Recombination between loxP and the bacterial chromosome. J Mol Biol 1981; 150: 487-507.
19. Hamilton DL, Abremski K. Site-specific recombination by the bacteriophage P1 lox-Cre system. Cre-mediated synapsis of two lox sites. J Mol Biol 1984; 178: 481-486.
20. Sauer B. Recycling selectable markers in yeast. Biotechniques 1994; 16: 1086-1088.
21. Onodera M et al. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 1997; 8: 1189-1194.
22. Hanazono Y, Yu JM, Dunbar CE, Emmons RVB. Green fluorescent protein retroviral vectors: low titer and high recombination frequency suggest a selective disadvantage. Hum Gene Ther 1997; 8: 1313-1319.
23. Sauer B, Henderson N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 1989; 17: 147-161.
24. Sauer B, Henderson N. Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. New Biol 1990; 2: 441-449.
25. Sauer B, Whealy M, Robbins A, Enquist L. Site-specific insertion of DNA into a pseudorabies virus vector. Proc Natl Acad Sci USA 1987; 84: 9108-9112.
26. Choulika A, Guyot V, Nicolas JF. Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site. J Virol 1996; 70: 1792-1798.
27. Russ AP, Friedel C, Grez M, von Melchner H. Self-deleting retrovirus vectors for gene therapy. J Virol 1996; 70: 4927-4932.
28. Bergemann J et al. Excision of specific DNA sequences from integrated retroviral vectors via site-specific recombination. Nucleic Acids Res 1995; 23: 4451-4456.
29. Fernex C, Dubreuil P, Mannoni P, Bagnis C. Cre/loxP-mediated excision of a neomycin resistance expression unit from an integrated retroviral vector increases long terminal repeat-driven transcription in human hematopoietic cells. J Virol 1997; 71: 7533-7540.
30. Westerman KA, Leboulch P. Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination. Proc Natl Acad Sci USA 1996; 93: 8971-9876.
31. Chalfie M et al. Green fluorescent protein as a marker for gene expression. Science 1994; 263: 802-805.
32. Subramanian S, Srienc F. Quantitative analysis of transient gene expression in mammalian cells using the green fluorescent protein. J Biotechnol 1996; 49: 137-151.
33. Hwang LH, Gilboa E. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J Virol 1984; 50: 417-424.
34. Sablitzky F, Jonsson JI, Cohen BL, Phillips RA. High frequency expression of integrated proviruses derived from enhancer trap retroviruses. Cell Growth Diff 1993; 4: 451-459.
35. Duch M et al. A correlation between dexamethasone inducibility and basal expression levels of retroviral vector proviruses. Nucleic Acids Res 1993; 21: 4777-4782.
36. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
37. Bowtell DD, Cory S, Johnson GR, Gonda TJ. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J Virol 1988; 62: 2464-2473.
38. Treisman J et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 1995; 85: 139-145.
39. Morgan RA et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
40. Anton M, Graham FL. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J Virol 1995; 69: 4600-4606.
41. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
42. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
43. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-982.
44. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
45. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
46. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
47. Jainchill JL, Aaronson SA, Todaro GJ. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969; 4: 549-553.
48. Kafatos FC, Jones CW, Efstratiadis A. Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure. Nucleic Acids Res 1979; 7: 1541-1552.
49. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
50. Southern E. Gel electrophoresis of restriction fragments. Methods Enzymol 1979; 68: 152-176.
51. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6-13.
52. Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning (2 edn), Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989.
53. Vanin EF et al. Development of high-titer retroviral producer cell lines by using Cre-mediated recombination. J Virol 1997; 71: 7820-7826.